Literature DB >> 33925569

Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.

Sebastian Zenovia1,2, Carol Stanciu1,2, Catalin Sfarti1,2, Ana-Maria Singeap1,2, Camelia Cojocariu1,2, Irina Girleanu1,2, Mihaela Dimache1,2, Stefan Chiriac1,2, Cristina Maria Muzica1,2, Robert Nastasa1,2, Laura Huiban1,2, Tudor Cuciureanu1,2, Anca Trifan1,2.   

Abstract

Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP) is a widely used non-invasive technique for concomitant assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). We aimed to evaluate the level both of hepatic steatosis and fibrosis as well as the associated risk factors in patients referred to our unit with clinically suspected NAFLD or diagnosed by abdominal ultrasonography. Two hundred four patients were prospectively included in this study and assessed by VCTE with CAP. The final analysis included 181 patients with reliable liver stiffness measurements (LSMs) (53% female, mean age 57.62 ± 11.8 years and BMI 29.48 ± 4.85 kg/m2). According to the cut-off values for steatosis grading, there were 10 (5.5%) patients without steatosis (S0), 30 (16.6%) with mild (S1), 45 (24.9%) moderate (S2), and 96 (53%) severe (S3) steatosis. Based on LSM, there were 73 (40.3%) patients without fibrosis (F0), 42 (23.2%) with mild (F1), 32 (17.7%) significant (F2), 19 (10.5%) advanced (F3) fibrosis, and 15 (8.3%) with cirrhosis (F4). In addition, we found an association between several metabolic components and hepatic steatosis and fibrosis. Thus, in the multivariate analysis, higher BMI, fasting plasma glucose, triglycerides, low-density lipoprotein cholesterol, and serum uric were associated with increased CAP. Furthermore, higher serum uric acid and alpha-fetoprotein together with lower platelets count and albumin levels were associated with increased LSM. The assessment of steatosis and fibrosis using VCTE and CAP should be performed in all patients with suspected or previously diagnosed NAFLD in units with available facilities.

Entities:  

Keywords:  CAP; NAFLD; fibrosis; steatosis

Year:  2021        PMID: 33925569     DOI: 10.3390/diagnostics11050787

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  37 in total

Review 1.  Hyperuricemia is associated with nonalcoholic fatty liver disease activity score in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Veeravich Jaruvongvanich; Wasin Ahuja; Kamonkiat Wirunsawanya; Karn Wijarnpreecha; Patompong Ungprasert
Journal:  Eur J Gastroenterol Hepatol       Date:  2017-09       Impact factor: 2.566

2.  Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease.

Authors:  L Fedchuk; F Nascimbeni; R Pais; F Charlotte; C Housset; V Ratziu
Journal:  Aliment Pharmacol Ther       Date:  2014-09-29       Impact factor: 8.171

3.  Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.

Authors:  Victor de Lédinghen; Grace Lai-Hung Wong; Julien Vergniol; Henry Lik-Yuen Chan; Jean-Baptiste Hiriart; Anthony Wing-Hung Chan; Faiza Chermak; Paul Cheung-Lung Choi; Juliette Foucher; Carmen Ka-Man Chan; Wassil Merrouche; Angel Mei-Ling Chim; Brigitte Le Bail; Vincent Wai-Sun Wong
Journal:  J Gastroenterol Hepatol       Date:  2016-04       Impact factor: 4.029

4.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  J Hepatol       Date:  2016-04-07       Impact factor: 25.083

5.  Spectrum of liver diseases in patients referred for Fibroscan: A single center experience in the Middle East.

Authors:  Bisher Sawaf; Adel Hajj Ali; Rola F Jaafar; Mariam Kanso; Deborah Mukherji; Mohamad J Khalife; Walid Faraj
Journal:  Ann Med Surg (Lond)       Date:  2020-07-25

6.  Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver.

Authors:  Miguel A Lanaspa; Laura G Sanchez-Lozada; Yea-Jin Choi; Christina Cicerchi; Mehmet Kanbay; Carlos A Roncal-Jimenez; Takuji Ishimoto; Nanxing Li; George Marek; Murat Duranay; George Schreiner; Bernardo Rodriguez-Iturbe; Takahiko Nakagawa; Duk-Hee Kang; Yuri Y Sautin; Richard J Johnson
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

7.  Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy.

Authors:  Magali Sasso; Stéphane Audière; Astrid Kemgang; Farid Gaouar; Christophe Corpechot; Olivier Chazouillères; Céline Fournier; Olivier Golsztejn; Stéphane Prince; Yves Menu; Laurent Sandrin; Véronique Miette
Journal:  Ultrasound Med Biol       Date:  2015-09-19       Impact factor: 2.998

8.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Authors:  Zobair Younossi; Maria Stepanova; Janus P Ong; Ira M Jacobson; Elisabetta Bugianesi; Ajay Duseja; Yuichiro Eguchi; Vincent W Wong; Francesco Negro; Yusuf Yilmaz; Manuel Romero-Gomez; Jacob George; Aijaz Ahmed; Robert Wong; Issah Younossi; Mariam Ziayee; Arian Afendy
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-14       Impact factor: 11.382

9.  Checkmate to liver biopsy in chronic hepatitis C?

Authors:  Anca Trifan; Carol Stanciu
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

10.  Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Authors:  Rachel M Williamson; Jackie F Price; Stephen Glancy; Elisa Perry; Lisa D Nee; Peter C Hayes; Brian M Frier; Liesbeth A F Van Look; Geoffrey I Johnston; Rebecca M Reynolds; Mark W J Strachan
Journal:  Diabetes Care       Date:  2011-04-08       Impact factor: 19.112

View more
  2 in total

1.  Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile.

Authors:  Sheng-Jie Shiue; Chao-Ling Cheng; Han-Shiang Shiue; Chun-Nan Chen; Sheng-Wei Cheng; Li-Wei Wu; Ganbolor Jargalsaikhan; Tze-Sian Chan; Hsin-Yi Lin; Ming-Shun Wu
Journal:  Nutrients       Date:  2022-07-06       Impact factor: 6.706

2.  Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter.

Authors:  Anca Trifan; Remus Stafie; Adrian Rotaru; Ermina Stratina; Sebastian Zenovia; Robert Nastasa; Laura Huiban; Tudor Cuciureanu; Cristina Muzica; Stefan Chiriac; Irina Girleanu; Ana-Maria Singeap; Catalin Sfarti; Camelia Cojocariu; Oana Petrea; Carol Stanciu
Journal:  J Clin Med       Date:  2022-10-09       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.